Literature DB >> 23553412

[Criteria for radiological assessment of therapy response: criteria-based appraisal].

M D'Anastasi1, N A Schramm, M F Reiser, A Graser.   

Abstract

Oncologic imaging and reporting are an important part of clinical trials and have to be performed according to standardized criteria that clearly define how certain changes in the size and number of tumorous lesions have to be rated. Knowledge of these criteria is not only crucial when interpreting cases for a clinical trial but may also be used as guidelines for everyday clinical reporting as they aid decision making and can increase the validity of radiologic reporting.This article summarizes the most important and frequently used criteria: the response evaluation criteria in solid tumors (RECIST) criteria which are only used in solid malignancies, the Choi criteria that have been designed for the assessment of gastrointestinal stroma tumors (GIST), and the Cheson criteria that are applied to malignant lymphomas. The compilation of these criteria is designed to be used as a repetitorium for experts and can also serve as training guidelines for junior radiologists who want to become involved in clinical trial reporting.

Entities:  

Mesh:

Year:  2013        PMID: 23553412     DOI: 10.1007/s00117-012-2435-8

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  29 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

3.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

4.  Response to treatment series: part 2, tumor response assessment--using new and conventional criteria.

Authors:  Vahid Yaghmai; Frank H Miller; Pedram Rezai; Al B Benson; Riad Salem
Journal:  AJR Am J Roentgenol       Date:  2011-07       Impact factor: 3.959

5.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

6.  Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.

Authors:  Ahsun Riaz; Frank H Miller; Laura M Kulik; Paul Nikolaidis; Vahid Yaghmai; Robert J Lewandowski; Mary F Mulcahy; Robert K Ryu; Kent T Sato; Ramona Gupta; Ed Wang; Talia Baker; Michael Abecassis; Al B Benson; Albert A Nemcek; Reed Omary; Riad Salem
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

Review 7.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

Review 8.  Radiologic measurements of tumor response to treatment: practical approaches and limitations.

Authors:  Chikako Suzuki; Hans Jacobsson; Thomas Hatschek; Michael R Torkzad; Katarina Bodén; Yvonne Eriksson-Alm; Elisabeth Berg; Hirofumi Fujii; Atsushi Kubo; Lennart Blomqvist
Journal:  Radiographics       Date:  2008 Mar-Apr       Impact factor: 5.333

Review 9.  Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

Authors:  Daniel S W Tan; George V Thomas; Michelle D Garrett; Udai Banerji; Johann S de Bono; Stan B Kaye; Paul Workman
Journal:  Cancer J       Date:  2009 Sep-Oct       Impact factor: 3.360

10.  Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

Authors:  Alejandro Forner; Carmen Ayuso; María Varela; Jordi Rimola; Amelia J Hessheimer; Carlos Rodriguez de Lope; María Reig; Luís Bianchi; Josep M Llovet; Jordi Bruix
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.